14 completed, 12 terminated, 1 recruiting, 1 unknown. 19 Phase 2, 8 Phase 1, 3 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 19 | Terminated 10, Completed 9 |
| Phase 1 | 8 | Completed 6, Terminated 2 |
| Not applicable | 3 | Terminated 2, Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow Leukemia, Lymphocytic, Chronic: new trials by email Literature Review of Leukemia, Lymphocytic, Chronic trials Research Report on Leukemia, Lymphocytic, Chronic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic Malignancy Standard - Metastatic Cancer, Cancer, Breast | Unknown | Weprom | 150 | 2022-06-01 | 2022-05-03 | |
| Intermittent Fasting and CLL/SLL Intermittent fast - Neoplasms, Leukemia, Lymphocytic, Chronic | Phase 1 | Completed | Eleah Stringer | 15 | 2021-02-03 | 2023-02-14 |
| Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL PBCAR20A, Fludarabine, Cyclophosphamide - Non-Hodgkin's Lymphoma, Relapsed, Chronic Lymphoid Leukemia in Relapse | Phase 1 / Phase 2 | Completed | Precision BioSciences, Inc. | 18 | 2020-03-24 | 2023-01-31 |
| Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Ibrutinib, Fludarabine, Pembrolizumab - B-Cell Chronic Lymphocytic Leukemia, B-Lymphocytic Leukemia, Chronic | Phase 2 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 15 | 2017-09-22 | 2026-01-30 |
| Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL ibrutinib, obinutuzumab, venetoclax - Leukemia, Lymphocytic, Chronic | Phase 2 | Completed | University of Ulm | 41 | 2016-09-01 | 2023-01-17 |
| A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors ASN002 Dose Escalation, ASN002 RD - Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell | Phase 1 / Phase 2 | Terminated | Asana BioSciences | 51 | 2015-05-01 | 2023-06-07 |
| MSC and HSC Coinfusion in Mismatched Minitransplants Mesenchymal stem cells, Isotonic solution - Leukemia, Myeloid, Acute, Leukemia, Lymphoblastic, Acute | Phase 2 | Terminated | University of Liege | 39 | 2010-07-01 | 2021-09-08 |
| Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related Donor and One Umbilical Cord Unit Haploidentical/cord transplant - Leukemia, Lymphocytic, Acute, Leukemia, Lymphocytic, Chronic | Phase 2 | Terminated | Medical College of Wisconsin | 1 | 2009-07-01 | 2015-11-20 |
| EL625 in Persistent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma cenersen sodium, Rituximab, Cyclophosphamide - Lymphoma, Small Lymphocytic, Leukemia, Lymphocytic, Chronic | Phase 2 | Terminated | David Rizzieri | 20 | 2008-02-01 | 2012-11-28 |
| Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL veltuzumab - NHL, Lymphoma, Non-Hodgkin | Phase 1 / Phase 2 | Completed | Gilead Sciences | 32 | 2008-01-01 | 2021-08-16 |
| Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients PCI-24781 - Neoplasms by Site, Lymphoma, Non-hodgkin | Phase 1 | Completed | Pharmacyclics LLC. | 36 | 2007-11-01 | 2011-09-28 |
| Alvocidib in Patients With Previously Treated Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Arising From Chronic Lymphocytic Leukemia (CLL) alvocidib - Leukemia, Lymphocytic, Chronic | Phase 2 | Completed | Sanofi | 165 | 2007-03-01 | 2013-02-12 |
| Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor Parathyroid Hormone (teriparatide) - Leukemia, Myeloid, Chronic, Anemia, Aplastic | Phase 2 | Terminated | The Emmes Company, LLC | 13 | 2006-09-01 | 2013-04-29 |
| Rituximab Plus Beta-Glucan in Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL) Rituximab, Beta-Glucan - Leukemia, Lymphocytic, Chronic, Lymphoma, Small Lymphocytic | Phase 2 | Terminated | University of Louisville | 2 | 2006-03-01 | 2018-05-04 |
| A Safety Study in Patients With Chronic Lymphocytic Leukemia SGN-40 (anti-huCD40 mAb) - Leukemia, Lymphocytic, Chronic | Phase 1 / Phase 2 | Completed | Seagen Inc. | 12 | 2005-07-01 | 2014-12-18 |
| Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL) forodesine hydrochloride (BCX-1777) - Leukemia, Lymphocytic, Chronic | Phase 2 | Completed | BioCryst Pharmaceuticals | 8 | 2005-06-01 | 2012-02-08 |
| Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies Non-Hodgkin's Lymphoma, Hodgkin's Disease | Recruiting | Dana-Farber Cancer Institute | 1500 | 2004-08-09 | 2026-10-13 | |
| A Pilot Study of Pivanex in Patients With Chronic Lymphocytic Leukemia Pivanex - Leukemia, Lymphocytic, Chronic, Lymphoma, Small Lymphocytic | Phase 2 | Terminated | Titan Pharmaceuticals | 28 | 2004-05-01 | 2005-08-30 |
| Post Transplant Donor Lymphocyte Infusion Donor Lymphocyte Infusion, Induction Chemotherapy - Leukemia, Myeloid, Chronic, Lymphomas | Phase 2 | Terminated | Masonic Cancer Center, University of Minnesota | 57 | 2004-01-01 | 2019-07-30 |
| Study of ONTAK in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) ONTAK - Leukemia, Lymphocytic, Chronic | Phase 2 | Completed | Eisai Inc. | 41 | 2003-03-01 | 2009-04-17 |
Showing 20 of 28. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (28) · Lymphoma, Non-Hodgkin (9) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (7) · Hodgkin Disease (6) · Leukemia (6) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (6) · Leukemia, Myeloid, Acute (4) · Lymphoma, B-Cell (4) · Multiple Myeloma (4) · Lymphoma (3) · Lymphoproliferative Disorders (3) · Neoplasms (3) · Anemia, Refractory, with Excess of Blasts (2) · Lymphoma, Follicular (2) · Myelodysplastic Syndromes (2)
Chronic Disease (28) · Disease Attributes (28) · Hemic and Lymphatic Diseases (28) · Immune System Diseases (28) · Immunoproliferative Disorders (28) · Neoplasms by Histologic Type (28) · Pathologic Processes (28) · Pathological Conditions, Signs and Symptoms (28) · Hematologic Diseases (27) · Leukemia, B-Cell (27) · Leukemia, Lymphoid (27) · Lymphatic Diseases (27) · Lymphoproliferative Disorders (25) · Neoplasms (25) · Leukemia (22)
Cyclophosphamide (4) · fludarabine (3) · fludarabine phosphate (3) · Rituximab (2) · ibrutinib (2) · Alemtuzumab (1) · Antilymphocyte Serum (1) · Bone Marrow Transplantation (1) · Busulfan (1) · Clofarabine (1) · Epoetin Alfa (1) · Induction Chemotherapy (1) · Isotonic Solutions (1) · Parathyroid Hormone (1) · Radiotherapy (1)
M.D. Anderson Cancer Center (3) · Masonic Cancer Center, University of Minnesota (2) · Pharmacyclics LLC. (2) · Asana BioSciences (1) · BioCryst Pharmaceuticals (1) · Dana-Farber Cancer Institute (1) · David Rizzieri (1) · Eisai Inc. (1) · Eleah Stringer (1) · French Innovative Leukemia Organisation (1) · Gilead Sciences (1) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (1) · Medical College of Wisconsin (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · Precision BioSciences, Inc. (1)
United States (21) · Argentina (2) · Australia (2) · Belgium (2) · Canada (2) · France (2) · Germany (2) · Brazil (1) · Italy (1) · Netherlands (1) · Puerto Rico (1) · United Kingdom (1)
Adrian U Wiestner, M.D. (1) · Alan List, MD (1) · Augustin Ferrant, MD, PhD (1) · Carlos Graux, MD, PhD (1) · Chantal Doyen, MD, PhD (1) · Chantal Lechanteur, PhD (1) · Colleen Delaney, MD (1) · Daniel Weisdorf, MD (1) · David Avigan, MD (1) · David Rizzieri, MD (1) · Dominik Selleslag, MD, PhD (1) · Dominique Bron, MD, PhD (1) · Edward Ball, M.D. (1)
PMID 17579184, PMID 20038235, PMID 20427701, PMID 21173095, PMID 22766223, PMID 26389849, PMID 31217161, PMID 38620092
U54HL081030 (1)